AR037742A1 - Compuestos derivados de piperazina, sus composiciones y su uso - Google Patents

Compuestos derivados de piperazina, sus composiciones y su uso

Info

Publication number
AR037742A1
AR037742A1 ARP020103961A ARP020103961A AR037742A1 AR 037742 A1 AR037742 A1 AR 037742A1 AR P020103961 A ARP020103961 A AR P020103961A AR P020103961 A ARP020103961 A AR P020103961A AR 037742 A1 AR037742 A1 AR 037742A1
Authority
AR
Argentina
Prior art keywords
alkyl
heteroaryl
heterocyclyl
aryl
compositions
Prior art date
Application number
ARP020103961A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR037742A1 publication Critical patent/AR037742A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un compuesto de fórmula (1) o una forma farmacéuticamente aceptable del mismo; a es 0, 1, 2, 3, 4, ó 5; b es 0, 1, ó 2; c es 0, 1, ó 2; d es 0, 1, 2, 3, ó 4; X es -O-, -S-, -CH2-, ó -NR6-; Y es arilo (C6-10) ó heteroarilo (C2-9); cada R1 es independientemente H-, HO-, halo-, alquil (C1-8)-, alquil (C1-8)-O-, HO-alquil (C1-8)-, NC-, H2N-, H2N-alquil (C1-8)-, HO-(C=O)-, alquil (C1-8)-(C=O)-, alquil (C1-8)-(C=O)-alquil (C1-8)-, H2N-(C=O)-, ó H2N-(C=O)-alquil (C1-8)-; cada R2 y R3 son independientemente H-, oxo, alquil (C1-8)-, cicloalquil (C3-8)-alquil (C1-8)-, aril (C6-10)-, aril (C6-10)-alquil (C1-8)-, HO-alquil (C1-8)-, alquil (C1-8)-O-alquil (C1-8)-, H2N-alquil (C1-8)-, alquil (C1-8)-NH-alquil (C1-8)-, [alquil (C1-8)]2N-alquil (C1-8)-, heterociclil (C2-9)-alquil (C1-8)-, cicloalquil (C3-8)-NH-alquil (C1-8)-, alquil (C1-8)-(C=O)-NH-alquil (C1-8)-, alquil (C1-8)-O-(C=O)-NH-alquil (C1-8)-, H2N-(C=O)-NH-alquil (C1-8)-, alquil (C1-8)-SO2-NH-alquil (C1-8)-, heteroaril (C2-9)-alquil (C1-8)-, H2N-(C=O)-, ó H2N-(C=O)-alquil (C1-8)-; R4 es [HO-(C=O)-][H2N-]alquil (C1-8)-, [HO-(C=O)-][alquil (C1-8)NH-]alquil (C1-8), [HO-(C=O)-][(alquil (C1-8))2N-]alquil (C1-8)-, HO-(C=O)-alquil (C1-8)-NH-, HO-(C=O)-alquil (C1-8)-NH-alquil (C1-8)-, [HO-(C=O)-alquil (C1-8)][alquil (C1-8)]N-, [HO-(C=O)-alquil (C1-8)][alquil (C1-8)]N-alquil (C1-8)-, [HO-(C=O)-alquil (C1-8)][alquil (C1-8)-SO2]N-, [HO-(C=O)-alquil (C1-8)][alquil (C1-8)-SO2]N-alquil (C1-8)-, [HO-(C=O)-alquil (C1-8)][alquil (C1-8)-(C=O)-]N-, [HO-(C=O)-alquil (C1-8)][alquil (C1-8)-(C=O)-]N-alquil (C1-8)-, [HO-(C=O)-alquil (C1-8)][alquil (C1-8)-O-(C=O)-]N-, [HO-(C=O)-alquil (C1-8)][alquil (C1-8)-O-(C=O)-]N-alquil (C1-8)-, [HO-(C=O)-alquil (C1-8)][alquil (C1-8) N-(C=O)-]N-, [HO-(C=O)-alquil (C1-8)][alquil (C1-8)-NH-(C=O)-]N-alquil (C1-8)-, HO-(C=O)-alquil (C1-8)-O-N=alquil (C1-8)-, HO-(C=O)-alquil (C1-8)-SO2- , HO-(C=O)-alquil (C1-8)-SO2-alquil (C1-8)-, HO-(C=O)-alquil (C1-8)-SO2-NH-, HO-(C=O)-alquil (C1-8)-SO2-NH-alquil (C1-8)-, HO-(C=O)-alquil (C1-8)-NH-SO2-, HO-(C=O)-alquil (C1-8)-NH-SO2-alquil (C1-8)-, HO-(C=O)-(C=O)-NH-SO2-, HO-(C=O)-(C=O)-NH-SO2-alquil (C1-8)-, HO-(C=O)-alquil (C1-8)-NH-(C=O)-NH-, HO-(C=O)-alquil (C1-8)-NH-(C=O)-NH-alquil (C1-8)-, HO-(C=O)-alquil (C1-8)-O-, HO-(C=O)-alquil (C1-8)-O-alquil (C1-8)-, HO-(C=O)-alquil (C1-8) sustituido con hidroxi, HO-(C=O)-alquenil (C2-8)-, heterociclil (C1-9)-alquil (C1-8)-O-, heterociclil (C1-9)-alquil (C1-8)-O-alquil (C1-8)-, heteroaril (C1-9)-alquil (C1-8)-O-, heteroaril (C1-9)-alquil (C1-8)-O-alquil (C1-8)-, heterociclil (C1-9)-O-, heterociclil (C1-9)-O- alquil (C1-8)-, heteroaril (C1-9)-O-, heteroaril (C1-9)-O-alquil (C1-8)-, HO-(C=O)-alquil (C1-8)-S-, HO-(C=O)-alquil (C1-8)-S-alquil (C1-8)-, heterociclil (C1-9)-alquil (C1-8)-S-, heterociclil (C1-9)-alquil (C1-8)-S-alquil (C1-8)-, heteroaril (C1-9)-alquil (C1-8)-S-, heteroaril (C1-9)-alquil (C1-8)-S-alquil (C1-8)-, heterociclil (C1-9)-S-, heterociclil (C1-9)-S-alquil (C1-8)-, heteroaril (C1-9)-S-, heteroaril (C1-9)-S-alquil (C1-8)-, HO-(C=O)-alquil (C1-8)-NH-SO2-NH-, HO-(C=O)-alquil (C1-8)-NH-SO2-NH-alquil (C1-8)-, HO-(C=O)-alquil (C1-8)-SO2-NH-(C=O)-, HO-(C=O)-alquil (C1-8)-SO2-NH-(C=O)-alquil (C1-8)-, HO-(C=O)-alquil (C1-8)-(C=O)-NH-SO2-, HO-(C=O)-alquil (C1-8)-(C=O)-NH-SO2-alquil (C1-8)-, HO-(C=O)-(C=O)-, HO-(C=O)-(C=O)-alquil (C1-8)-, HO-(C=O)-alquil (C1-8)-(C=O)-, HO-(C=O)-alquil (C1-8)-(C=O)-alquil (C1-8)-, HO-(C=O)-heterociclil (C1-9)-(C=O)-, HO-(C=O)-heteroaril (C1-9)-(C=O)-, NC-NH-(C=O)-, NC-NH-(C=O)-alquil (C1-8), [alquil (C1-8)-SO2-NH-(C=O)-][H2N-]alquil (C1-8)-, alquil (C1-8)-SO2-NH-(C=O)-, alquil (C1-8)-SO2-NH-(C=O)-alquil (C1-8)-, alquil (C1-8)-SO2-NH-(C=O)-alquil (C1-8)-NH-, alquil (C1-8)-SO2-NH-(C=O)-alquil (C1-8)-NH-alquil (C1-8)-, [alquil (C1-8)-SO2-NH-(C=O)-alquil (C1-8)][alquil (C1-8)]N-, [alquil (C1-8)-SO2-NH-(C=O)-alquil (C1-8)][alquil (C1-8)]N-alquil (C1-8)-, alquil (C1-8)-SO2-NH-(C=O)-alquil (C1-8)-NH-SO2-, alquil (C1-8)-SO2-NH-(C=O)-alquil (C1-8)-NH-SO2-alquil (C1-8)-, alquil (C1-8)-SO2-NH-(C=O)-alquil (C1-8)-SO2-NH-, alquil (C1-8)-SO2-NH-(C=O)-alquil (C1-8)-SO2-NH-alquil (C1-8)-, alquil (C1-8)-SO2-NH-(C=O)-alquil (C1-8)-SO2-, alquil (C1-8)-SO2-NH-(C=O)-alquil (C1-8)-SO2-alquil (C1-8)-, alquil (C1-8)-SO2-NH-(C=O)-(C=O)-, alquil (C1-8)-SO2-NH-(C=O)-(C=O)-alquil (C1-8)-, alquil (C1-8)-SO2-NH-(C=O)-alquil (C1-8)-(C=O)-, alquil (C1-8)-SO2-NH-(C=O)-alquil (C1-8)-(C=O)-alquil (C1-8)-, NH-alquil (C1-8)-SO2-NH-(C=O)-, NC-alquil (C1-8)-SO2-NH-(C=O)-alquil (C1-8)-, HO-alquil (C1-8)-SO2-NH-(C=O)-, HO-alquil (C1-8)-SO2-NH-(C=O)-alquil (C1-8)-, alquil (C1-8)-SO2-NH-(C=O)-alquenil (C2-8)-, heterociclil (C1-9)-SO2-NH-(C=O)-, heterociclil (C1-9)-SO2-NH-(C=O)-alquil (C1-8)-, heterociclil (C1-9)-alquil (C1-8)-SO2-NH-(C=O)-, heterociclil (C1-9)-alquil (C1-8)-SO2-NH-(C=O)-alquil (C1-8)-, aril (C6-10)-SO2-NH-(C=O)-, aril (C6-10)-SO2-NH-(C=O)-alquil (C1-8)-, heteroaril (C1-9)-SO2-NH-(C=O)-, heteroaril (C1-9)-SO2-NH-(C=O)-alquil (C1-8)-, H2N-SO2-NH-(C=O)-, H2N-SO2-NH-(C=O)-alquil (C1-8)-, alquil (C1-8)-NH-SO2-NH-(C=O)-, alquil (C1-8)-NH-SO2-NH-(C=O)-alquil (C1-8)-, [alquil (C1-8)]2N-SO2-NH-(C=O)-, [alquil (C1-8)]2N-SO2-NH-(C=O)-alquil (C1-8), alquil (C1-8)-SO2-NH-(C=O)-alquil (C1-8)-O-, alquil (C1-8)-SO2-NH-(C=O)-alquil (C1-8)-O-alquil (C1-8)-, alquil (C1-8)-(C=O)-NH-SO2-, H2N-SO2-alquil (C1-8)-, alquil (C1-8)-(C=O)-NH-SO2-alquil (C1-8)-, NC-alquil (C1-8)-(C=O)-NH-SO2-alquil (C1-8)-, HO-(alquil C1-C8)-(C=O)-NH-SO2-alquil (C1-8)-, aril (C6-10)-(C=O)-NH-SO2-, aril (C6-10)-(C=O)-NH-SO2-alquil (C1-8)-, heteroaril (C1-9)-(C=O)-NH-SO2-, heteroaril (C1-9)-(C=O)-NH-SO2-alquil (C1-8)-, heterociclil (C1-9)-(C=O)-NH-SO2-, heterociclil (C1-9)-(C=O)-NH-SO2-alquil (C1-8)-, H2N-(C=O)-NH-SO2-, H2N-(C=O)-NH-SO2-alquil (C1-8)-, alquil (C1-8)-NH-(C=O)-NH-SO2-, alquil (C1-8)-NH-(C=O)-NH-SO2-alquil (C1-8)-, [alquil (C1-8)]2-N-(C=O)-NH-SO2-, [alquil (C1-8)]2-N-(C=O)-NH-SO2-alquil (C1-8)-, aril (C6-10)-NH-(C=O)-NH-SO2-, aril (C6-10)-NH-(C=O)-NH-SO2-alquil (C1-8)-, heteroaril (C1-9)-NH-(C=O)-NH-SO2-, heteroaril (C1-9)-NH-(C=O)-NH-SO2-alquil (C1-8)-, alquil (C1-8)-O-(C=O)-NH-SO2-, alquil (C1-8)-O-(C=O)-NH-SO2-alquil (C1-8)-, aril (C6-10)-oxi-(C=O)-NH-SO2-, aril (C6-10)-oxi-(C=O)-NH-SO2-alquil (C1-8)-, alquil (C1-8)-SO2-NH-(C=O)-O-, alquil (C1-8)-SO2-NH-(C=O)-O-alquil (C1-8)-, alquil (C1-8)-SO2-NH-(C=O)-NH-, alquil (C1-8)-SO2-NH-(C=O)-NH-alquil (C1-8)-, aril (C6-10)-SO2-NH-(C=O)-O-, aril (C6-10)-SO2-NH-(C=O)-O-alquil (C1-8)-, aril (C6-10)-SO2-NH-(C=O)-NH-, aril (C6-10)-SO2-NH-(C=O)-NH-alquil (C1-8)-, heteroaril (C1-9)-SO2-NH-(C=O)-O-, heteroaril (C1-9)-SO2-NH-(C=O)-O-alquil (C1-8)-, NH2-SO2-NH-(C=O)-O-, NH2-SO2-NH-(C=O)-O-alquil (C1-8)-, heteroaril (C1-9)-SO2-NH-(C=O)-NH-, heteroaril (C1-9)-SO2-NH-(C=O)-NH-alquil (C1-8)-, NH2-SO2-NH-(C=O)-NH-, NH2-SO2-NH-(C=O)-NH-alquil (C1-8)-, HO-(C=O)-alquil (C1-8)-NH-(C=O)-O-, HO-(C=O)-alquil (C1-8)-NH-(C=O)-O-alquil (C1-8)-, HO-(C=O)-alquil (C1-8)-O-(C=O)-NH-, HO-(C=O)-alquil (C1-8)-O-(C=O)-NH-alquil (C1-8)-, alquil (C1-8)-(C=O)-NH-SO2-NH-, alquil (C1-8)-(C=O)-NH-SO2-NH-alquil (C1-8), aril (C6-10)-(C=O)-NH-SO2-NH-, aril (C6-10)-(C=O)-NH-SO2-NH-alquil (C1-8), heteroaril (C1-9)-(C=O)-NH-SO2-NH-, heteroaril (C1-9)-(C=O)-NH-SO2-NH-alquil (C1-8), NH2-(C=O)-NH-SO2-NH-, NH2-(C=O)-NH-SO2-NH-alquil (C1-8), heteroaril (C1-9)-alquil (C1-8)-(C=O)-, heterociclil (C1-9)-alquil (C1-8)-(C=O)-, heteroaril (C1-9)-alquil (C1-8)-(C=O)-alquil (C1-8)-, heterociclil (C1-9)-alquil (C1-8)-(C=O)-alquil (C1-8)-, heteroaril (C1-9)-(C=O)-alquil (C1-8)-, ó heterociclil (C1-9)-(C=O)-alquil (C1-8); ó, si Y es un grupo heteroarilo (C2-9), entonces R4 puede ser también HO-(C=O)-alquil (C1-8)-, heteroaril (C1-9)-, heterociclil (C1-9)-, heteroaril (C1-9)-alquil (C1-8), ó heterociclil (C1-9)-alquil (C1-8); cada R5 es independientemente H-, HO-, halo-, NC-, HO-(C=O)-, H2N-, alquil (C1-8)-NH-, [alquil (C1-8)]2N-, alquil (C1-8)-, alquil (C1-8)-O-, HO-alquil (C1-8)-, alquil (C1-8)-O-alquil (C1-8)-, H2N-alquil (C1-8)-, alquil (C1-8)-NH-alquil (C1-8)-, [alquil (C1-8)]2N-alquil (C1-8)-, alquil (C1-8)-(C=O)-, alquil (C1-8)-(C=O)-alquil (C1-8)-, aril (C6-10)-, heteroaril (C2-9)-, aril (C6-10)-oxi-, H2N-(C=O)-, H2N-(C=O)-alquil (C1-8)-, alquil (C1-8)-NH-(C=O)-, alquil (C1-8)-NH-(C=O)-alquil (C1-8)-, [alquil (C1-8)]2N-(C=O)-, [alquil (C1-8)]2-N-(C=O)-alquil (C1-8)-, cicloalquil (C3-8)-, alquil (C1-8)-SO2-, NC-alquil (C1-8)-, alquil (C1-8)-(C=O)-NH-, H2N-(C=O)-NH-, ó H2N-(C=O)-NH-alquil (C1-8)-; y R6 es H, alquil (C1-8)-, alquil (C1-8)-(C=O)-, aril (C6-10)-(C=O)-, heteroaril (C2-9)-(C=O)-, H2N-(C=O)-, alquil (C1-8)-NH-(C=O)-, [alquil (C1-8)]2N-(C=O)-, alquil (C1-8)-O-(C=O)-, ó alquil (C1-8)-SO2-. Composiciones farmacéuticas que comprenden un compuesto de fórmula (1) y un vehículo farmacéuticamente aceptable, y procedimientos de uso de los compuestos y composiciones descriptos en este documento para el tratamiento o prevención de un trastorno o afección que puede tratarse o prevenirse por antagonización del receptor CCR1 en un mamífero.
ARP020103961A 2001-10-22 2002-10-21 Compuestos derivados de piperazina, sus composiciones y su uso AR037742A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33860101P 2001-10-22 2001-10-22

Publications (1)

Publication Number Publication Date
AR037742A1 true AR037742A1 (es) 2004-12-01

Family

ID=23325393

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020103961A AR037742A1 (es) 2001-10-22 2002-10-21 Compuestos derivados de piperazina, sus composiciones y su uso

Country Status (35)

Country Link
US (1) US7098212B2 (es)
EP (1) EP1438298B1 (es)
JP (1) JP2005507923A (es)
KR (1) KR20040047941A (es)
CN (1) CN1575283A (es)
AP (1) AP2004003008A0 (es)
AR (1) AR037742A1 (es)
AT (1) ATE456559T1 (es)
BG (1) BG108674A (es)
BR (1) BR0213452A (es)
CA (1) CA2463272C (es)
CZ (1) CZ2004519A3 (es)
DE (1) DE60235249D1 (es)
DK (1) DK1438298T3 (es)
EA (1) EA006243B1 (es)
EC (1) ECSP045073A (es)
EE (1) EE200400088A (es)
ES (1) ES2337241T3 (es)
HN (1) HN2002000300A (es)
HR (1) HRP20040289A2 (es)
HU (1) HUP0401735A3 (es)
IL (1) IL160974A0 (es)
IS (1) IS7180A (es)
MA (1) MA27142A1 (es)
MX (1) MXPA04002423A (es)
NO (1) NO20041631L (es)
OA (1) OA12670A (es)
PA (1) PA8556901A1 (es)
PE (1) PE20030568A1 (es)
PL (1) PL370548A1 (es)
SK (1) SK1852004A3 (es)
TN (1) TNSN04072A1 (es)
UY (1) UY27503A1 (es)
WO (1) WO2003035627A1 (es)
ZA (1) ZA200402090B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
WO2003013571A1 (en) * 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7132539B2 (en) * 2002-10-23 2006-11-07 The Procter & Gamble Company Melanocortin receptor ligands
GB0224917D0 (en) * 2002-10-25 2002-12-04 Novartis Ag Organic compounds
US20040092529A1 (en) * 2002-10-30 2004-05-13 Pfizer Inc Methods of using piperazine derivatives
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7968548B2 (en) * 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
AU2005268030B2 (en) 2004-08-06 2009-02-19 Otsuka Pharmaceutical Co., Ltd. Aromatic compounds
US7777035B2 (en) 2005-06-22 2010-08-17 Chemocentryx, Inc. Azaindazole compounds and methods of use
UA95777C2 (en) * 2005-06-22 2011-09-12 Кемосентрикс, Инк. Azaindazole compounds and methods of use
US7790726B2 (en) 2005-08-16 2010-09-07 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
DK1957073T3 (da) 2005-12-05 2014-05-12 Otsuka Pharma Co Ltd Lægemiddel
DE102006029795A1 (de) * 2006-06-27 2008-01-03 Schebo Biotech Ag Neue Harnstoff-Derivate und deren Verwendungen
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
UA95978C2 (ru) 2006-10-02 2011-09-26 Оцука Фармас'Ютікел Ко., Лтд. Ингибитор активации stat3/5
JP5424330B2 (ja) * 2007-07-26 2014-02-26 国立大学法人大阪大学 インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤
KR20120098908A (ko) 2009-12-23 2012-09-05 아이언우드 파마슈티컬스, 인코포레이티드 Ｃｒｔｈ２ 조절제
US20130259830A1 (en) 2010-07-12 2013-10-03 Ironwood Pharmaceuticals, Inc. Crth2 modulators
US20130216552A1 (en) 2010-07-12 2013-08-22 Ironwood Pharmaceuticals, Inc. Crth2 modulators
FR2976943B1 (fr) * 2011-06-23 2013-07-12 Metabolys Derives de piperazine, leurs procedes de preparation et leurs utilisations dans le traitement de l'insulinoresistance
CN103012318B (zh) * 2012-11-25 2014-12-10 大理学院 氟苄基取代哌嗪类化合物及其制备和医药用途
US11840543B2 (en) 2017-05-24 2023-12-12 The University Of Queensland Compounds and uses
EP3668840A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
GB201918692D0 (en) 2019-12-18 2020-01-29 Cambridge Entpr Ltd Treatment and prognosis of pancreatic cancer
CN113754616B (zh) * 2021-09-27 2023-07-18 北京工商大学 一种反式-3-苯硫基-γ-内酯的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (es) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
IT1156990B (it) * 1978-04-27 1987-02-04 Geymonat Sud Spa Procedimento per la preparazione del cloridrato di p clorofenossiacetil piperonilpierazina
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
IT1255704B (it) 1992-09-30 1995-11-10 Boehringer Mannheim Italia Ammine eterocicliche utili nella terapia dell'asma e dell'infiammazione delle vie aeree
IL110040A (en) 1993-06-29 2000-07-16 Nissan Chemical Ind Ltd Pyridazinone derivatives their preparation and pharmaceutical compositions comprising them
HUP9602489A3 (en) 1995-01-11 1998-01-28 Samjin Pharm Co Ltd Piperazine derivatives, process for producing them and pharmaceutical compositions containing them
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
CA2404626A1 (en) * 2000-03-31 2001-10-04 Pfizer Products Inc. Novel piperazine derivatives
WO2002032901A2 (en) 2000-10-19 2002-04-25 Pfizer Products Inc. Bridged piperazine derivatives
UY27003A1 (es) 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer

Also Published As

Publication number Publication date
CA2463272C (en) 2009-11-17
IL160974A0 (en) 2004-08-31
CA2463272A1 (en) 2003-05-01
PA8556901A1 (es) 2003-11-12
CZ2004519A3 (cs) 2004-12-15
KR20040047941A (ko) 2004-06-05
HUP0401735A3 (en) 2005-06-28
US20040034034A1 (en) 2004-02-19
HUP0401735A2 (hu) 2005-01-28
DE60235249D1 (de) 2010-03-18
MXPA04002423A (es) 2004-05-31
ECSP045073A (es) 2004-05-28
MA27142A1 (fr) 2005-01-03
HRP20040289A2 (en) 2004-10-31
ES2337241T3 (es) 2010-04-22
PE20030568A1 (es) 2003-07-07
SK1852004A3 (sk) 2005-03-04
ATE456559T1 (de) 2010-02-15
OA12670A (en) 2006-06-20
UY27503A1 (es) 2003-06-30
HN2002000300A (es) 2003-10-17
EA006243B1 (ru) 2005-10-27
JP2005507923A (ja) 2005-03-24
CN1575283A (zh) 2005-02-02
NO20041631L (no) 2004-05-26
TNSN04072A1 (fr) 2006-06-01
EP1438298B1 (en) 2010-01-27
PL370548A1 (en) 2005-05-30
ZA200402090B (en) 2005-05-23
US7098212B2 (en) 2006-08-29
EA200400466A1 (ru) 2004-08-26
BR0213452A (pt) 2004-11-09
EE200400088A (et) 2004-10-15
BG108674A (en) 2005-04-30
IS7180A (is) 2004-03-11
WO2003035627A1 (en) 2003-05-01
DK1438298T3 (da) 2010-04-12
AP2004003008A0 (en) 2004-06-30
EP1438298A1 (en) 2004-07-21

Similar Documents

Publication Publication Date Title
AR037742A1 (es) Compuestos derivados de piperazina, sus composiciones y su uso
AR039660A1 (es) Inhibidores de aril-heteroariloxi-ariloxi-pirimidin-2,4,6-triona metaloproteinasa
AR044749A1 (es) Inhibidor de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que lo usan
JP2002527434A5 (es)
CO5700720A2 (es) Derivados de n-(quinolin-5l) alquilamida-sustituida; n-alquilquinolin-5-carboxamida-sustituida; n-alquilisoquinolin-5-carboxamida-sustituida; n-(isoquinolin-5-yl) alquilamida-sustituida y procesos para su preparacion
AR011093A1 (es) Compuestos derivados de sulfonil urea, composicion farmaceutica que los contiene y procedimiento para su uso.
EP2311806A3 (en) Dihydropyridine-, pyridine-, benzopyranone- and triazoloquinazoline derivatives, their preparation and their use as adenosine receptor antagonists
RU2003116060A (ru) Карбамидзамещенные имидазохинолиновые эфиры
AR040047A1 (es) 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de la 5-hidroxitriptamina-6
AR047682A1 (es) Derivados tetrahidroisoquinolinilo de quinazolina e isoquinolina
AR036606A1 (es) Tratamiento con antranilamidas artropodicidas
TR200100439T2 (tr) 1H-İmidazopiridin türevleri
DK1181299T3 (da) C-2-modificerede erythromycinderivater
UY26048A1 (es) Derivados de piridopiranoacepinas, su preparacion y su aplicacion terapeutica
CA2451006A1 (en) 1,2,4-trioxolane antimalarials
CA2468649A1 (en) Adenosine a2a receptor antagonists
KR930007882A (ko) 세포독성 비시클로[7.3.1]트리데 - 4 - 센 - 2,6디인 화합물 및 그의 제조방법
MXPA04009283A (es) Nuevos derivados de alcoxipiridina.
AR037770A1 (es) Compuesto inhibidor de la integrasa del vih, composicion farmaceutica que lo comprende y uso del mismo para prepararla
ES2123546T3 (es) Uso de derivados de 1-(aminoalquil)-3-quinoxalina-2-ona para la preparacion de composiciones neuroprotectoras.
ATE344230T1 (de) Triphenylbutenderivate zur behandlung von neurologischen störungen
ATE134640T1 (de) Neue verbindungen, ''leusstroducsins'' gennant, ihre herstellung und therapeutische verwendungen
DK1007530T3 (da) 6-O-substituerede erythromycinforbindelser samt fremgangsmåde til fremstilling heraf
UY25807A1 (es) Caprolactamas sustituidas, composiciones farmacéuticas que las contienen, y su uso en el tratamiento de tumores.
DE69132580D1 (de) 7-Acyl-3-(substituierte carbamoyloxy) Cephem Verbindungen, Verfahren zu ihrer Herstellung und Anwendung

Legal Events

Date Code Title Description
FB Suspension of granting procedure